Pan-cancer analysis identifies LPCATs family as a prognostic biomarker and validation of LPCAT4/WNT/β-catenin/c-JUN/ACSL3 in hepatocellular carcinoma

• DOI: 10.18632/aging.204723
• Publication Date: 2023-06-08T16:29:45Z
• Authors: Yaoyong Lu; Hongfeng Liang; Xiaoyin Li; Haiwen Chen; Changfu Yang
• Keywords: Liver Cancer

Lipid remodeling regulators are now being investigated as potential therapeutic targets for cancer therapy a result of their involvement, which includes promoting cells’ adaptation to the restricted environment. Lysophosphatidylcholine acyltransferases (LPCATs, LPCAT1-4) enzymes that regulate bio-membranes. The functions these in largely unknown. In current study, we found genes belonging LPCAT family participated tumor advancement and were strongly linked dismal prognosis many different malignancies. We constructed LPCATs scores model explored this pan-cancer. Malignant pathways pan-cancer positively related scores, all had strong links microenvironment (TME). Multiple immune-associated features TME likewise associated with higher scores. addition, score functioned prognostic marker immune checkpoint inhibitor (ICI) therapies patients cancer. LPCAT4 enhanced cell growth cholesterol biosynthesis by up-regulating ACSL3 hepatocellular carcinoma (HCC). WNT/β-catenin/c-JUN signaling pathway mediated LPCAT4’s regulation on ACSL3. These findings demonstrated might be used immunotherapy prognosis-related biomarkers. Specifically, could treatment target HCC.